Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to comply with scheduled visits, treatment pan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.~* Body weight ≥35 kg.~* Sweat chloride value ≥ 60 mmol/L from test results obtained during screening.~* Subjects must have an eligible CFTR genotype:~  * Cohorts 1A, 1B, 1C: Heterozygous for F508del and a minimal function mutation known or predicted not to respond to TEZ and/or IVA.~ * Cohorts 2A, 2B: Homozygous for F508del.~* Subjects must have an FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height at the Screening Visit.~* Stable CF disease as judged by the investigator.~* Willing to remain on a stable CF medication regimen through the planned end of treatment or if applicable the Safety Follow-up Visit.~Exclusion Criteria:~* History of any comorbidity that in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject.~* History of cirrhosis with portal hypertension.~* Risk factors for Torsade de Pointes.~* History of hemolysis.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.~* Clinically significant abnormal laboratory values at screening.~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before the first dose of study drug.~* Lung infection with organisms associated with a more rapid decline in pulmonary status.~* An acute illness not related to CF within 14 days before the first dose of study drug.~* A standard digital ECG demonstrating QTc \>450 msec at screening.~* History of solid organ or hematological transplantation.~* History or evidence of cataract or lens opacity determined to be clinically significant by the ophthalmologist or optometrist, based on the ophthalmologic examination during the Screening Period.~* History of alcohol or drug abuse in the past year, including but not limited to, cannabis, cocaine, and opiates, as deemed by the investigator.~* Ongoing or prior participation in an investigational drug study with certain exceptions.~* Use of commercially available CFTR modulator within 14 days before screening (applies only to Cohorts 1A, 1B, and 1C).~* Pregnant or nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): None
- Part 1 Cohort 1A: TC (Type: EXPERIMENTAL): None
- Part 1 Cohort 1B: TC (Type: EXPERIMENTAL): None
- Part 1 Cohort 1C: TC (Type: EXPERIMENTAL): None
- Part 2 Cohort 2A: TEZ/IVA (Type: ACTIVE_COMPARATOR): None
- Part 2 Cohort 2A: TC (Type: EXPERIMENTAL): None
- Part 2 Cohort 2B: TEZ/IVA (Type: ACTIVE_COMPARATOR): None
- Part 2 Cohort 2B: TC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).